Literature DB >> 11061080

[The value of serum C-reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer].

K Kato1, Y Hitsuda, Y Kawasaki, T Igishi, K Yasuda, M Mikami, M Watanabe, M Miyata, T Sasaki, E Shimizu.   

Abstract

We retrospectively reviewed the information in our data base concerning 127 patients with advanced non-small-cell lung cancer. Seventeen pretreatment clinical variables including serum C-reactive protein (CRP) were analyzed to determine the factors related to survival using Cox's proportional hazards model. Univariate analysis revealed that eleven explanatory variables were significant. In multivariate statistical technique for those variables, six were selected as significant factors. The highest hazard ratio was observed in the serum CRP (3.82). The other factors were therapy (2.52), serum lactate dehydrogenase (2.41), serum total protein (2.20), white blood cell counts (1.98) and performance status (1.80). Median survival times estimated by the Kaplan-Meier procedures in patients with normal CRP (CRP < 0.2 mg/dl) and high positive CRP (CRP > or = 3.0 mg/dl) were 24.9 months and 3.7 months, respectively. These results suggest that serum CRP is an independent survival determinant in advanced non-small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061080

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  8 in total

1.  Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

Authors:  Michał Hrab; Karolina Olek-Hrab; Andrzej Antczak; Zbigniew Kwias; Tomasz Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-26

2.  Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.

Authors:  Faruk Tas; Derya Duranyildiz; Andac Argon; Hilal Oğuz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

4.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

Authors:  G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

5.  Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer.

Authors:  Tingting Zhao
Journal:  Wien Klin Wochenschr       Date:  2022-07-06       Impact factor: 1.704

6.  Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.

Authors:  B Gagnon; M Abrahamowicz; Y Xiao; M-E Beauchamp; N MacDonald; G Kasymjanova; H Kreisman; D Small
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

7.  Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis.

Authors:  Wei-Min Gao; Rork Kuick; Randal P Orchekowski; David E Misek; Ji Qiu; Alissa K Greenberg; William N Rom; Dean E Brenner; Gilbert S Omenn; Brian B Haab; Samir M Hanash
Journal:  BMC Cancer       Date:  2005-08-23       Impact factor: 4.430

8.  [The prognostic value of detection of serum C-reactive protein in the patients with stage I lung cancer].

Authors:  Ye Xu; Ziming Li; Yang Shen-Tu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.